Tsuchimoto Kim R 4
4 · Monopar Therapeutics · Filed Oct 3, 2023
Insider Transaction Report
Form 4
Tsuchimoto Kim R
Director
Transactions
- Exercise/Conversion
Common Stock
2023-09-30+9,956→ 41,430 total - Tax Payment
Common Stock
2023-09-30$0.62/sh−3,444$2,135→ 37,986 total - Exercise/Conversion
Restricted Stock Units
2023-09-30−9,956→ 105,513 total→ Common Stock (9,956 underlying)
Footnotes (5)
- [F1]Represents shares acquired on vesting and settlement of restricted stock units.
- [F2]On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
- [F3]On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
- [F4]Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
- [F5]On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.